FK633: A Potent and Selective Platelet GPIIb/IIIa Antagonist
نویسندگان
چکیده
Platelet activation and aggregation have been shown to play a central role in thromboembolic disorders (20,35,37). Platelets are activated by a variety of agonists. They adhere to the injured blood vessel walls and, subsequently, aggregate. These processes lead to the formation of occlusive thrombi in the lumen of the injured vessel (16,23,53). The efficacy of such common antiplatelet agents as aspirin and ticlopidine is limited because they inhibit only some of the many pathways in platelet activation (2,33,39). Antagonism of the platelet glycoprotein (GP) IIb/IIIa receptor represents an attractive antiplatelet strategy, because it inhibits the final common step in platelet aggregation irrespective of the inducing agonist (3,12,13). The inhibition of platelet function with some GPIIb/IIIa antagonists has led to significant clinical benefits in reducing acute coronary ischemic syndrome (47–49). FK633 is a potent and selective GPIIb/IIIa antagonist that inhibits human platelet aggregation induced by a wide variety of agonists (3). In vivo experiments suggest that it is effective in the prevention of arterial thrombus formation and in the suppression of reocclusion and restenosis in the injured vessel after thrombolysis (3,4,28). In this review, we present the pharmacological profile, pharmacokinetics, toxicology, and some clinical data on FK633, and discuss the future direction for GPIIb/IIIa antagonists.
منابع مشابه
Glycoprotein IIb/IIIa antagonist FK633 could not prevent neointimal thickening in stent implantation model of canine coronary artery.
The platelet glycoprotein (GP) IIb/IIIa receptor antagonist appears to reduce the need for revascularization after coronary angioplasty. However, since the effect of GP IIb/IIIa receptor antagonist on the in-stent neointimal thickening has not been clarified, we examined it in the canine model. The beagle dogs were assigned to the control (n=7) or the GP IIb/IIIa receptor antagonist FK633 group...
متن کاملDensity of Platelet GPIIb-IIIa and Bleeding Severity in Iranian Patients with Glanzmann’s Thrombasthenia
متن کامل
Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.
BACKGROUND Microembolic signals (MES) as detected by transcranial Doppler ultrasound define an individual stroke risk in patients with carotid artery disease. To study the composition of MES in vivo, we used the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist tirofiban, a highly selective platelet aggregation inhibitor. METHODS AND RESULTS Twenty-four patients with recent cerebral or r...
متن کاملComparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
Glycoprotein (GP) IIb/IIIa is pivotal in homotypic platelet aggregation and may also be involved in the heterotypic adhesion of leukocytes and tumor cells to platelets. This study was primarily undertaken to compare the antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist, XV454, to that of abciximab in 2 flow models of platelet thrombus formation: (1) direct shear-induced platele...
متن کاملReversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor.
Platelet glycoprotein (GP) IIb-IIIa inhibitors may become useful antithrombotic agents. Ro 43-5054 is a low molecular weight, noncyclic, peptidomimetic inhibitor that is three orders of magnitude more potent than RGDS in inhibiting fibrinogen binding to purified GPIIb-IIIa and in preventing platelet aggregation. Comparisons of RGDS and Ro 43-5054 in cell adhesion assays showed that, in contrast...
متن کامل